BusinessData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association CongressBy Nasdaq OMXMay 18, 2017, 10:03 AM UTC
BusinessData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association CongressBy Nasdaq OMXMay 18, 2017, 10:03 AM UTC
BusinessData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association CongressBy Nasdaq OMXMay 18, 2017, 10:03 AM UTC
BusinessAmarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular CareBy Nasdaq OMXMay 18, 2017, 10:01 AM UTC
BusinessAmarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular CareBy Nasdaq OMXMay 18, 2017, 10:01 AM UTC
BusinessXeris Pharmaceuticals Announces Closing of $30 Million FinancingBy Nasdaq OMXMay 17, 2017, 11:00 PM UTC
BusinessData from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017By Nasdaq OMXMay 17, 2017, 9:05 PM UTC
BusinessCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV SymposiumBy Nasdaq OMXMay 17, 2017, 12:05 PM UTC
